New Phase III data from the DISCOVER-1 and DISCOVER-2 studies show improvement in joint and skin symptoms of psoriatic arthritis at week 52, and an indication expansion of guselkumab is currently under review. It would be another advance in treatment options for this burdensome autoimmune disease.